Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of years. According to GlobalData Drugs Database, more than 400 companies ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

In recent years, more and more celebrities — like Elon Musk and Whoopi Goldberg — have spoken up about using GLP-1 ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...